₹32.15
−1.71%NSE close, 16 Nov 2026
−7.24%
Sudarshan Pharma Industries is a small cap company, listed on NSE under the symbol SUDARSHAN. At ₹32.15 a share, the market values the whole company at ₹818 crore.
₹ crore. Consolidated figures.
| Line | Sep 2026 |
|---|---|
| Sales | 217 |
| Expenses | 196 |
| Operating profit | 20.6 |
| Operating margin | 9.5% |
| Other income | 1.9 |
| Interest | 10.4 |
| Depreciation | 1.4 |
| Profit before tax | 10.8 |
| Tax | 3.0 |
| Net profit | 8.1 |
| EPS (₹) | 0.31 |
Resignation of Mr Nirav Shah as Company Secretary & Compliance Officer of the company w.e.f. November 09, 2026.
₹ crore, financial years to March.
Not filed yet.
₹ crore, at each year's end and the latest half year.
| Line | Sep 2026 |
|---|---|
| Shareholders’ equity | 195 |
| Borrowings | 390 |
| Total liabilities | 566 |
| Fixed assets | 73.0 |
| Investments | 0 |
| Cash and equivalents | 1.2 |
| Total assets | 762 |
₹ crore, by financial year, and the latest half year.
| Line | 6M to Sep 2026 |
|---|---|
| From operations | −52.7 |
| From investing | −68.5 |
| From financing | 121 |
| Spent on fixed assets | −1.7 |
| Free cash flow | −54.4 |
Margins, returns, debt, tax and cash.
Not filed yet.
Issue of Securities - In continuation of the Company''s letter dated 30/Oct/2026 (ref. no. SPIL/CS/2026-2027/72), the Board of Directors at its Meeting held on 29/Oct/2026 have approved the proposal to raising of funds through issue and allotment of Convertible Warrants upto…
We are submitting herewith the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/Sep/2026